ACB Stock Price: Aurora Cannabis Inc. is in freefall after Q4 earnings call and CIBC analyst downgrade
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get Premium without limits for only $9.99 for the first month
Access all our articles, insights, and analysts.
UNLOCK OFFER- NYSE:ACB tumbled by nearly 30% as next year’s outlook brings a troubling forecast.
- CIBC analyst downgrades price target and the overall outlook for Aurora.
- Aurora CEO admits that the company is no longer the top dog in the Canadian cannabis industry.
It has been another disappointing quarter for NYSE:ACB investors as the once prominent marijuana company continues to tumble closer to obscurity. On Wednesday shares fell almost 30%, hitting a new 52-week low and closing the trading session at $5.17. The stock has now fallen nearly 90% over the past year and is lagging the performance of the S&P 500 by 100%.
The Q4 earnings call was another bleak look into the future of the cannabis industry as CEO Miguel Martin openly acknowledged that Aurora has “slipped from its top position in Canadian consumer” and will likely shift its focus to higher-end, premium products. The change in product selection comes as both the Canadian and American cannabis markets have been overrun by discount brands, from which Aurora is now trying to distance themselves. By offering a more premium selection of products such as edibles and concentrates, the firm hopes to re-establish itself as a go-to brand in the recreational cannabis sector.
ACB stock forecast
The bottom line is that the company lost nearly $3.3 billion in its fiscal year 2020 and gave an even worse outlook for 2021. The Edmonton based firm forecasts Q1 revenue between $60 million and $64 million, which would mean anywhere from a 5% to 11% decline in cannabis revenue for Aurora. CIBC analyst John Zamparo slashed his price target from $20 down to $12, meaning that there may be some upside to the stock at its current levels. Even for bargain investors, Aurora is probably not worth the risk with projected declining revenues and no signs of Federal legalization in the United States, it may be beyond the point of saving itself.
- NYSE:ACB tumbled by nearly 30% as next year’s outlook brings a troubling forecast.
- CIBC analyst downgrades price target and the overall outlook for Aurora.
- Aurora CEO admits that the company is no longer the top dog in the Canadian cannabis industry.
It has been another disappointing quarter for NYSE:ACB investors as the once prominent marijuana company continues to tumble closer to obscurity. On Wednesday shares fell almost 30%, hitting a new 52-week low and closing the trading session at $5.17. The stock has now fallen nearly 90% over the past year and is lagging the performance of the S&P 500 by 100%.
The Q4 earnings call was another bleak look into the future of the cannabis industry as CEO Miguel Martin openly acknowledged that Aurora has “slipped from its top position in Canadian consumer” and will likely shift its focus to higher-end, premium products. The change in product selection comes as both the Canadian and American cannabis markets have been overrun by discount brands, from which Aurora is now trying to distance themselves. By offering a more premium selection of products such as edibles and concentrates, the firm hopes to re-establish itself as a go-to brand in the recreational cannabis sector.
ACB stock forecast
The bottom line is that the company lost nearly $3.3 billion in its fiscal year 2020 and gave an even worse outlook for 2021. The Edmonton based firm forecasts Q1 revenue between $60 million and $64 million, which would mean anywhere from a 5% to 11% decline in cannabis revenue for Aurora. CIBC analyst John Zamparo slashed his price target from $20 down to $12, meaning that there may be some upside to the stock at its current levels. Even for bargain investors, Aurora is probably not worth the risk with projected declining revenues and no signs of Federal legalization in the United States, it may be beyond the point of saving itself.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.